by Elena Iemma | Mar 29, 2024 | News
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ — Read the publication. In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk –...
by Elena Iemma | Mar 15, 2024 | Blog
Tregitopes by Another Name? OK, sometimes, I am late to the party. Maybe … allowing ideas, like parties, to mature, means getting there at exactly the right time. That just happened with this article and I’d like to share it with you. It’s...
by Elena Iemma | Sep 10, 2021 | Events
EpiVax participated in the 2021 International Society for Vaccines (ISV) Annual Virtual Congress September 13-15, 2021. The 2021 Congress was a busy one, it’s been a difficult but innovative period for the vaccine development community. Multiple EpiVax...
by Elena Iemma | Jul 6, 2021 | News
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...
by Elena Iemma | May 17, 2021 | News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
